Annual Conference

"From Concept to the Clinic"

"[We're] not talking about something that may happen someday. [We're] talking about what's happening now."

Howard McLeod, Pharm.D.
Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center

November 16

The community will turn its attention to the best strategies for integrating personalized medicine in clinical settings during the third day of the conference. In addition to exploring the implications of clinical insights from representatives at pioneering health care providers around the country, participants will consider novel perspectives from patients and providers as they share their thoughts on existing and forthcoming technologies. Representatives of the Trump administration have also been invited to deliver keynote addresses on the third day of the conference.

7:00 a.m. — Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m. — Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., President, CEO, Aravive Biologics; Chairman, Board of Directors, PMC

8:10 a.m. — Clinical Adoption of Personalized Medicine: A Two-Part Discussion

Pioneering health care providers have begun to explore the business models, operational processes, IT infrastructure and educational programs that are needed to catalyze the paradigm shift toward personalized medicine. This two-part session on clinical adoption will examine the strategic and day-to-day challenges clinical organizations face as they seek to integrate personalized medicine in clinical settings — and the solutions they employ to address those challenges.

SESSION CHAIR | Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare

8:15 A.M. | The Case for Personalized Medicine in the Clinic: The View From the Corner Office

Inspiring an organizational commitment to a new way of practicing medicine requires visionary leadership. This fireside chat will highlight the viewpoints and approaches of leaders who are spearheading efforts to adopt personalized medicine at clinical institutions, with an eye on the value proposition for changing existing norms and practices.

  • MODERATOR | Howard McLeod, Pharm.D., Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
  • Ronald A. Paulus, M.D., President and CEO, Mission Health
  • Jeffrey R. Balser, M.D., Ph.D., Dean of Vanderbilt University School of Medicine, President and CEO, Vanderbilt University Medical Center

9:00 A.M. | Practicing Personalized Medicine: Lessons From the Front Lines

To successfully integrate personalized medicine into a health system, administrators and clinicians must also design and implement new processes related to program infrastructure and informatics; help educate physicians and patients about the field; and inspire cultural change within the institution. During this panel discussion, a group of early adopters will share lessons learned from implementing pilot programs across the United States. 

  • MODERATOR | Daryl Pritchard, Ph.D., Vice President, Science Policy, Personalized Medicine Coalition
  • Bonnie J. Addario, Founder, Chair, Bonnie J. Addario Lung Cancer Foundation; Lung Cancer Survivor
  • Scott A. Beck, M.B.A., Administrator, Center for Individualized Medicine, Mayo Clinic
  • Timothy Cannon, M.D., Clinical Director, Molecular Tumor Board, Inova Schar Cancer Institute
  • Peter Hulick, M.D., M.M.Sc., Medical Director, Center for Personalized Medicine, NorthShore University HealthSystem
  • Marc S. Williams, M.D., Director, Genomic Medicine Institute, Geisinger

10:15 a.m. — Networking Break: Sponsored by Moffitt Cancer Center

Light refreshments provided

10:45 a.m. — Harvard Business School Case Study — Intermountain Healthcare: Pursuing Precision Medicine

Intermountain has a long history of being at the forefront of health care quality improvement and the development of treatment protocols. In 2013, Intermountain Precision Genomics (IPG) was started with Dr. Lincoln Nadauld as its Executive Director. IPG focused on stage 4 cancer patients and performed three distinct functions: genomics equencing, interpretation of sequencing results with recommendations for precision therapies, and drug acquisition and reimbursement. A paper published in February 2017 reported that in addition to having a higher quality of life, patients who received the targeted therapies had progression-free survival rates of almost twice as long as other patients. The purpose of our case discussion will be to assess these efforts, to consider their broader applicability and to review IPG’s plans for the future.

  • PRESENTER | Richard Hamermesh, D.B.A., Senior Fellow, Former MBA Class of 1961, Professor of Management Practice, Harvard Business School

11:45 a.m. — Overview of the International Landscape for Personalized Medicine

KEYNOTE | Kristin Pothier, Global Head of Life Sciences, Parthenon-EY

12:00 p.m. — Lunch Break

A bag lunch will be provided

1:00 p.m. — Personalized Medicine at FDA: An Inside Look at the Agency's Priorities for the Field

INTRODUCTION | Cynthia A. Bens, Vice President, Public Policy, Personalized Medicine Coalition
KEYNOTE | Scott Gottlieb, M.D., Commissioner, FDA

2:00 p.m. — The Patient Perspective on Personalized Medicine

INTRODUCTION | Susan McClure, Founder, Publisher, Genome magazine
KEYNOTE | Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation

2:30 p.m. — Patient 2.0: Exploring the Future of Personalized Medicine

Many observers speculate that the coming wave of gene editing, gene therapy, direct-to-consumer genetic tests and the personalized use of wearables will change the psychology, sociology, economy and efficacy of health care. Informed by the previous panel discussions, this conversation will examine the future of personalized medicine and the merits of these emerging trends.

  • MODERATOR | Robert C. Green, M.D., M.P.H., Director, G2P Research Program, Associate Director for Research, Partners Personalized Medicine, Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Broad Institute and Harvard Medical School
  • Sandro Galea, M.D., Dr.P.H., Dean, Robert A. Knox Professor, School of Public Health, Boston University
  • Tom Miller, Founder, Managing Partner, GreyBird Ventures LLC
  • Michael Snyder, Ph.D., Stanford W. Ascherman Professor and Chair, Department of Genetics Director, Center for Genomics and Personalized Medicine, Stanford University School of Medicine

3:30 p.m. — Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition